AZA197

AZA197 is a selective small molecule inhibitor of Cdc42.AZA197 suppresses colon cancer cell proliferation, cell migration, invasion and increases apoptosis by down-regulating the PAK1 and ERK signaling pathways in vitro. AZA197 reduces tumor growth and significantly increases mouse survival in SW620 tumor xenografts. AZA197 can be used for the study of colon cancer^[1]. In Vitro:AZA197 (1-100 μM, 24 h) promotes LDH release and inhibits Cdc42 activation in SW620 colon cancer cells^[1].
AZA197 (1-10 μM, 24-72 h) significantly inhibits the proliferation of SW620 and HT-29 cells in a dose- and time-dependent manner^[1].
AZA197 (2-10 μM, 24 h) induces SW620 cell apoptosis and causes cell cycle arrest^[1].
AZA197 (1-5 μM, 24 h) dose-dependently significantly inhibits the migration and invasion abilities of SW620 and HT-29 cells^[1].
AZA197 (2-10 μM, 24 h) inhibits Cdc42, thereby disrupting its crucial functions in regulating cell morphology and movement in SW620 and HT-29 cells^[1].
AZA197 (2-10 μM, 24 h) inhibits Cdc42, thereby suppressing the downstream PAK-ERK signaling axis in SW620 and HT-29 cells^[1].
In Vivo:AZA197 (100 μg, dissolved in 100 μL of 30% DMSO (HY-Y0320C), i.p., once daily for 2 weeks or 100 days) significantly inhibits tumor growth and significantly prolonged the survival time of tumor-bearing mice in a colon cancer xenograft model^[1].